Endonovo Therapeutics Announces Binding Letter of Intent to Acquire Rio Grande Neurosciences …

LOS ANGELES, CA–(Marketwired – Jul 11, 2016) – Endonovo Therapeutics, Inc. (OTCQB: ENDV) — a developer of bioelectronic devices and medicines, announced today it has executed a binding letter of intent (LOI) to acquire Rio Grande Neurosciences, Inc. (RGN), a privately-held clinical stage developer of non-invasive Electroceuticals™ for the treatment of neuro-inflammation and central nervous system diseases and disorders. The LOI is binding, but subject to the execution of a definitive purchase agreement, shareholder approvals from both companies and Endonovo raising additional capital. The parties expect to sign a definitive agreement within the third quarter ending September 30, 2016 and close at the same time or shortly thereafter. Endonovo has paid $500,000 towards the purchase price through the issuance of a note. Pursuant to the LOI, Endonovo will be acquiring RGN…


Link to Full Article: Endonovo Therapeutics Announces Binding Letter of Intent to Acquire Rio Grande Neurosciences …